<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131313</url>
  </required_header>
  <id_info>
    <org_study_id>POI-02818</org_study_id>
    <secondary_id>NIP-02-005</secondary_id>
    <nct_id>NCT00131313</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.</brief_title>
  <official_title>A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Valley Hematology and Oncology Medical Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mena, Raul, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmatech Oncology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>East Valley Hematology and Oncology Medical Group</source>
  <brief_summary>
    <textblock>
      This research study measures the safety and efficacy of the combination of three drugs that
      are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia
      (CLL). These drugs are being given together for investigational purposes as the specific
      combination of these three drugs has not been approved for treatment of CLL by the FDA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Lymphocytic Leukemia (CLL) is the most common form of adult leukemia in the U.S.
      Recent experience with Nipent in conjunction with Rituxan has shown that this combination is
      well tolerated and is clinically promising. It is expected that the addition of Cytoxan in
      patients with previously untreated CLL and patients who have relapsed or failed prior therapy
      may benefit from combined therapy using Nipent, Cytoxan and Rituxan. It is unknown how the
      addition of Cytoxan will affect the toxicity profile of the Rituxan and Nipent regimen,
      however, patients will be monitored for toxicities. It is expected that bone marrow
      toxicities will not increase to unreasonable levels.

      The primary objective of the study is to determine the overall efficacy response rate
      following treatment with Nipent, Cytoxan and Rituxan of patients with previously untreated or
      treated CLL. The secondary objectives of the study are to determine the duration of response,
      time to progression, time to treatment failure and to evaluate the toxicity of this
      combination of drugs and the incidence and severity of adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2003</start_date>
  <completion_date>April 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
  </secondary_outcome>
  <enrollment>180</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nipent, Cytoxan, Rituxan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage II, III or IV Chronic Lymphocytic Leukemia

          -  Disease requires chemotherapeutic treatment

          -  CT or MRI scan confirming measurable tumor size

          -  Documentation of CD markers

          -  Up to one prior treatment regimen

          -  Expected survival greater than 6 months

          -  ECOG performance status of 0-2

          -  Adequate renal, bone marrow and liver functions

          -  Negative pregnancy test (females of childbearing potential)

          -  Must agree to use acceptable birth control, if fertile

          -  Must complete Informed Consent

          -  No heart disease and must have adequate cardiac function

          -  Must test negative for viral Hepatitis B and C

        Exclusion Criteria:

          -  More than one prior treatment for Chronic Lymphocytic Leukemia

          -  Known sensitivity to Nipent, Rituxan or Cytoxan or any component of these drugs

          -  Known HIV or AIDS illness

          -  Thyroid disease requiring medication

          -  History of any malignancy that could affect the diagnosis or assessment of the study
             treatment

          -  Pregnancy or breast feeding

          -  Evidence of Hepatitis B or C infection

          -  Inability to comply with the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul Mena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Valley Hematology and Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tracy Latimer</last_name>
    <phone>720-917-7478</phone>
    <email>tracyl@pharmatech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwest Alabama Cancer Center, PC</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Daugherty, MD</last_name>
    </contact>
    <investigator>
      <last_name>James Daugherty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Valley Hematology and Oncology Medical Group</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul R Mena, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raul R Mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Area Cancer Research Group</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L Robles, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert L Robles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lalita Pandit, MD, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lalita Pandit, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lalita Pandit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Coast Hematology/Oncology Medical Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glen R Justice, MD</last_name>
    </contact>
    <investigator>
      <last_name>Glen R Justice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert A. Moss, M.D. FACP, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert A Moss, MD, FACP</last_name>
    </contact>
    <investigator>
      <last_name>Robert A Moss, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hematology Oncology Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter S Kennedy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter S Kennedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North County Oncology</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren S Paroly, MD</last_name>
    </contact>
    <investigator>
      <last_name>Warren S Paroly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology Oncology Specialists</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemary E McIntyre, MD,PharmD</last_name>
    </contact>
    <investigator>
      <last_name>Rosemary E McIntyre, MD,PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer and Blood Institute Medical Group</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert H Lemon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert H Lemon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Teresa Comprehensive Cancer Center</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neelesh S Bangalore, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Neelesh S Bangalore, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Group of North County</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Bessudo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Bessudo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Clinic, PC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Headley, DO</last_name>
    </contact>
    <investigator>
      <last_name>David Headley, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mile High Oncology</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Schrier, MD, DO</last_name>
    </contact>
    <investigator>
      <last_name>David Schrier, MD, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palm Beach Institute of Hematology and Oncology</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eyal Meiri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eyal Meiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medhi M Moezi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Medhi M Moezi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osceola Cancer Center</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge G Otoya, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jorge G Otoya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pasco Hernando Oncology Associates, PA</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K.S. Kumar, MD</last_name>
    </contact>
    <investigator>
      <last_name>K.S. Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pasco Pinellas Cancer Center</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Arevalo-Araujo, MD,PharmD,PA</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Arevalo-Araujo, MD,PharmD,PA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta Oncology Associates, PC</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark R Keaton, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mark R Keaton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spalding Oncology Services</name>
      <address>
        <city>Griffin</city>
        <state>Georgia</state>
        <zip>30224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rao Moravineni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rao Moravineni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Walters, MD</last_name>
    </contact>
    <investigator>
      <last_name>Theodore Walters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Assoc. of Northern Illinois</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilesh D Mehta, MD, FACP</last_name>
    </contact>
    <investigator>
      <last_name>Nilesh D Mehta, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Oncology Hematology Consultants</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Cooper, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maureen Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnett Cancer Care</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas I Jones, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas I Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveed Chowhan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Naveed Chowhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentucky Cancer Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Ghazal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hassan Ghazal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhu Chaudhry, MD, MBBS</last_name>
    </contact>
    <investigator>
      <last_name>Madhu Chaudry, MD, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Oncology Hematology Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yudhishtra Markan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yudhishtra Markan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auerbach Hematology Oncology Associates, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Auerbach, MD, PharmD,FACP</last_name>
    </contact>
    <investigator>
      <last_name>Michael Auerbach, MD, PharmD,FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesee Cancer &amp; Blood Disease Treatment Center, PC</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rizwan Danish, MD, FACP</last_name>
    </contact>
    <investigator>
      <last_name>Rizwan Danish, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Regional Cancer &amp; Blood Center</name>
      <address>
        <city>Freesoil</city>
        <state>Michigan</state>
        <zip>49411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed S Behairy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ahmed S Behairy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy O'Rourke, MD</last_name>
    </contact>
    <investigator>
      <last_name>Timothy O'Rourke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Branson Oncology Clinic</name>
      <address>
        <city>Branson</city>
        <state>Missouri</state>
        <zip>65616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pairote Jaroonwanichkul, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pairote Jaroonwanichkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Hematology Oncology Specialists, Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvin Schergen, MD, PharmD,FACP</last_name>
    </contact>
    <investigator>
      <last_name>Alvin Schergen, MD, PharmD,FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sierra Nevada Oncology Care</name>
      <address>
        <city>Carson City</city>
        <state>Nevada</state>
        <zip>89703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Perez-Cardona, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jorge Perez-Cardona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Nafees Nagy, MD</last_name>
    </contact>
    <investigator>
      <last_name>M. Nafees Nagy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Hematologic Disease</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Zrada, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Zrada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ellioth Fishkin, MD</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellioth Fishkin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ellioth Fishkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westchester Hematology Oncology Associates</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gino Bottino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gino Bottino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Dakota Clinic/Odyssey Research</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bipinkumar R Amin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bipinkumar R Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Health System Hospitals</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Douglas Trochelman, MD</last_name>
    </contact>
    <investigator>
      <last_name>R. Douglas Trochelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nashat Y. Gabrail, MD, Inc.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nashat Y Gabrail, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nashat Y Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sambandam and Joseph Associates, Inc</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Plakyil J Joseph, MD</last_name>
    </contact>
    <investigator>
      <last_name>Plakyil J Joseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George F Geils, Jr., MD</last_name>
    </contact>
    <investigator>
      <last_name>George F Geils, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal P Christiansen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Neal P Christiansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Family Cancer Center</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Gravenor, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Gravenor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C. Michael Jones, MD, PC</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Michael Jones, MD, PC</last_name>
    </contact>
    <investigator>
      <last_name>C. Michael Jones, MD, PC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JPS Center for Cancer Care</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra M Prow, MD</last_name>
    </contact>
    <investigator>
      <last_name>Debra M Prow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cache Valley Cancer Treatment &amp; Research Clinic, Inc.</name>
      <address>
        <city>Logan</city>
        <state>Utah</state>
        <zip>84341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Ben-Jacob, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ali Ben-Jacob, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Outreach Associates, PC</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Forrest Swan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Forest Swan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Care, PC</name>
      <address>
        <city>Richlands</city>
        <state>Virginia</state>
        <zip>24641</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhaven V Pillai, MD, PharmD,FACP</last_name>
    </contact>
    <investigator>
      <last_name>Madhaven V Pillai, MD, PharmD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pharmatech.com/</url>
    <description>Pharmatech - The Research Link website</description>
  </link>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2005</study_first_submitted>
  <study_first_submitted_qc>August 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2005</study_first_posted>
  <last_update_submitted>August 17, 2005</last_update_submitted>
  <last_update_submitted_qc>August 17, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2005</last_update_posted>
  <keyword>Leukemia</keyword>
  <keyword>Cancer</keyword>
  <keyword>Nipent</keyword>
  <keyword>Rituxan</keyword>
  <keyword>Cytoxan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

